Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now early-phase tilt

Depressive Disorder: early-phase trial registry

15 of 48 indexed Depressive Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #297 of 28,707 conditions by registered trial count.

48 US clinical trials · 15 currently recruiting · #297 of 28,707 conditions by registered trial count

Depressive Disorder: 48 US clinical trials tracked, 15 recruiting.

Depressive Disorder is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Mclean Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition depressive-disorder

OPEN 15 | RECR 31% | LATE 4 | EARLY 12 | RANK #297 | SPON 2

Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)

Gastric Adenocarcinoma54.2%Lung Non-Small Cell Carcinom47.9%Overactive Bladder43.8%Brain Cancer41.7%Depressive Disorder (this)31%
Open-enrollment share among volume-matched conditions near Depressive Disorder

Depressive Disorder lists 15 open slots (31% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Depressive Disorder is recruiting below its size-band peers.

    15 of 48 indexed trials (31.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Depressive Disorder trials is spread across many organizations.

    Mclean Hospital accounts for 2 of 48 trials (4.2%). 40 distinct sponsors appear on at least one study for this condition label.

  3. Typical Depressive Disorder enrolment sits around 90 participants.

    Median target enrolment is 90 among the 48 trials that report a genuine target (sentinel values excluded). 25 of those (52.1%) plan for fewer than 100 participants.

  4. Depressive Disorder research is mostly interventional.

    42 interventional and 6 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 29Phase 32Phase 42

Open and recent trials

48 total, page 1 of 1

RECRUITING NA 1,500 participants

Unified Protocol: Community Connections

University of Miami

NCT06038721

RECRUITING 500 participants

Ketamine Treatment Plans for Chronic Conditions

RIVER Foundation

NCT06038409

RECRUITING NA 300 participants

Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes

Colorado State University

NCT05543083

RECRUITING NA 238 participants

Whole Health in VA Mental Health: Omnis Salutis

VA Office of Research and Development

NCT05400252

RECRUITING 150 participants

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

San Francisco Veterans Affairs Medical Center

NCT06080646

RECRUITING NA 144 participants

Research Evaluating Vagal Excitation AND Anatomical Links

University of Minnesota

NCT06143293

RECRUITING NA 128 participants

Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

Weill Medical College of Cornell University

NCT05925322

RECRUITING NA 90 participants

Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change

Carilion Clinic

NCT06671158

RECRUITING NA 80 participants

A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults

New York University

NCT06508450

RECRUITING NA 70 participants

Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness

Massachusetts General Hospital

NCT05962879

RECRUITING Phase 2 70 participants

Mindfulness Engaged Neurostimulation for Depression

University of California, San Diego

NCT06399406

RECRUITING Phase 2 60 participants

Depressed Mood Improvement Through Nicotine Dosing 3

Vanderbilt University Medical Center

NCT05746273

RECRUITING Phase 2 50 participants

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

National Institute of Mental Health (NIMH)

NCT06511908

RECRUITING NA 40 participants

Enhancing Brain And Mental Health Through Breathing Practice

Mayo Clinic

NCT07369752

RECRUITING Phase 2 30 participants

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Yale University

NCT05786066

ACTIVE NOT RECRUITING NA 800 participants

Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents

Rhode Island Hospital

NCT03626103

ACTIVE NOT RECRUITING Phase 2 60 participants

Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension

Vanderbilt University Medical Center

NCT05746546

ACTIVE NOT RECRUITING 42 participants

Imaging to Improve Brain Stimulation

VA Office of Research and Development

NCT04016402

ACTIVE NOT RECRUITING NA 15 participants

PRISM for Depression and Anxiety in Young Adults With Cancer

Dana-Farber Cancer Institute

NCT06502483

COMPLETED NA 6,205 participants

Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations

Washington University School of Medicine

NCT04162847

COMPLETED NA 895 participants

Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression

Rutgers University

NCT01829100

COMPLETED Phase 3 837 participants

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Otsuka Pharmaceutical Development & Commercialization

NCT02196506

COMPLETED 715 participants

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Medibio Limited

NCT05708222

COMPLETED Phase 4 340 participants

Optimizing Electroconvulsive Therapy for Depression

New York State Psychiatric Institute

NCT00045916

COMPLETED Phase 2 319 participants

An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder

Sanofi

NCT00358631

COMPLETED NA 205 participants

Depression Attention for Women Now (The DAWN Study)

University of Washington

NCT01096316

COMPLETED NA 168 participants

Virtual Reality Job Interview Training in Severe Mental Illness

University of Michigan

NCT03049813

COMPLETED Phase 2 161 participants

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Janssen Research & Development

NCT02498392

COMPLETED Phase 3 132 participants

Magnetic Stimulation Therapy for Treating Vascular Depression

University of Iowa

NCT00044798

COMPLETED Phase 2 132 participants

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Tonix Pharmaceuticals

NCT05686408

COMPLETED NA 125 participants

Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

Boston University Charles River Campus

NCT05120232

COMPLETED NA 122 participants

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

Tal Medical

NCT02452892

COMPLETED NA 116 participants

Text-Message-Based Depression Prevention for High-Risk Youth in the ED

Rhode Island Hospital

NCT02332239

COMPLETED NA 108 participants

Multifaceted Depression and Cardiovascular Program

University of Southern California

NCT02069912

COMPLETED 89 participants

Feasibility of Collateral Information Review and Its Impact on Clinical Decision-Making

Mclean Hospital

NCT04635748

COMPLETED Phase 2 85 participants

Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas

US Department of Veterans Affairs

NCT00223652

COMPLETED NA 74 participants

Family Promoting Positive Emotions Pilot Study

Vanderbilt University

NCT05223842

COMPLETED 57 participants

Insulin Resistance in Patients With Major Depression

Stanford University

NCT01106313

COMPLETED NA 50 participants

Improving Retention of Hispanics Receiving Antidepressant Therapy

New York State Psychiatric Institute

NCT00057642

COMPLETED Phase 1 46 participants

Effect of Nicotine on Brain Reward Pathways

Mclean Hospital

NCT02346539

COMPLETED Phase 1 40 participants

Effects of Therapist Behavior on the Treatment of Depressed Adolescents

University of Denver

NCT00073359

COMPLETED NA 38 participants

Group Therapy for Women Prisoners With Comorbid Substance Use and Depression

Brown University

NCT00606996

COMPLETED NA 38 participants

Acute Aerobic Exercise and Neuroplasticity in Depression

Medical University of South Carolina

NCT02839837

COMPLETED Phase 1 33 participants

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

GlaxoSmithKline

NCT00439868

COMPLETED Phase 4 31 participants

Memantine Augmentation of Antidepressants

University of Massachusetts, Worcester

NCT00344682

COMPLETED NA 25 participants

EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy

Massachusetts General Hospital

NCT02676882

COMPLETED NA 24 participants

Duloxetine for the Treatment of Dysthymia

Stanford University

NCT00185575

COMPLETED NA 13 participants

TMS for Adults With Autism and Depression

Medical University of South Carolina

NCT02939560

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 9
Phase 3 2
Phase 4 2

Named interventions

Most-linked intervention names on Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Ketamine Drug
2 trials
EnBrace HR Dietary supplement
1 trials
Modified Unified Protocol (UP+) Behavioral
1 trials
NeuroStar® TMS device (Neuronetics, Atlanta, GA) Device
1 trials
Control (EUC) Behavioral
1 trials
iDOVE Intervention (ED+text) Behavioral
1 trials
Written Information Behavioral
1 trials

US sites by state

Facility locations filed on Depressive Disorder trials. A trial with sites in several states counts in each.

California 12 trials
Massachusetts 9 trials
Florida 7 trials
New York 6 trials
Colorado 5 trials
Rhode Island 4 trials
Pennsylvania 4 trials
North Carolina 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Depressive Disorder page

48 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 15 Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mclean Hospital sponsors the most Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Mclean Hospital's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Depressive Disorder condition card totals 48 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.